Investment
Features
FeesSafety
Academy
More
Pluang+

Private-public crossover ETF XOVR returns 5.64% post-SpaceX IPO, outperforming major growth benchmarks.

Market News
15 Sep 2026
PRNewsWire
View Source
Bullish
Private-public crossover ETF XOVR returns 5.64% post-SpaceX IPO, outperforming major growth benchmarks.

The ERShares Private-Public Crossover ETF (XOVR) achieved a 5.64% cumulative NAV return from the SpaceX IPO on June 12, 2026, through September 4, 2026, outperforming major growth indexes like the Russell 1000 Growth and Nasdaq 100. Since its relaunch in August 2024, XOVR has generated a 40.42% return, slightly trailing its ER30TR Index but beating other benchmarks such as the Dow Jones Industrial Average. The ETF uniquely invests in both private and public companies, maintaining positions through transitions like SpaceX's IPO. This approach offers retail investors access to private-market growth opportunities traditionally limited to institutional investors.

The ERShares Private-Public Crossover ETF (XOVR) is noted here with Pluang's Technology-sector snapshot for context. For readers following technology stocks, here is Pluang's market snapshot as of Sep 15, 2026 20:11 WIB: out of 150 priced US tech stocks, 52 rose and 91 fell today. Among notable movers, ASML Holding NV gained 3.18%, while Coinbase Global, Inc. and Strategy Inc. declined by 3.89% and 3.53%, respectively.

More News

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma A/S regained full control of its TransCon technology for metabolic diseases from Novo Nordisk, allowing it to independently develop and sell treatments, including for obesity. The company also authorized a $400 million share repurchas...

Market News
Bullish
4 hours ago
Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold following mixed results from its drug trials. The lung disease drug tozorakimab showed strong Phase III results and received FDA priority review, signaling potential future growth. H...

Analyst Insights
Neutral
4 hours ago
Northrop Grumman completes full inert Sentinel ICBM assembly, advancing toward 2027 test launch.

Northrop Grumman completes full inert Sentinel ICBM assembly, advancing toward 2027 test launch.

Northrop Grumman and the U.S. Air Force successfully completed the vertical integration of a full-scale inert Sentinel intercontinental ballistic missile (ICBM) at Vandenberg Space Force Base, marking a key milestone in the missile's development. The...

Market News
Bullish
4 hours ago
MakeMyTrip remains a Buy with planned IPO and strong business diversity supporting growth

MakeMyTrip remains a Buy with planned IPO and strong business diversity supporting growth

MakeMyTrip Limited is maintained as a Buy due to its upcoming IPO of its Indian subsidiary, which could unlock value and help fund convertible redemptions. The company’s diversified business model, particularly in hotels and buses, helps offset chall...

Market News
Bullish
4 hours ago
Dave & Buster's shares drop 12% after Q2 sales miss, but signs of recovery emerge.

Dave & Buster's shares drop 12% after Q2 sales miss, but signs of recovery emerge.

Dave & Buster's stock fell 12% following a weaker-than-expected Q2 report with revenue down 2.4% and a net loss of $12.5 million. The company saw a 2.9% decline in same-store sales, driven by a 9% drop in entertainment sales, partially offset by food...

Company Fundamentals
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App